Published in BMJ on September 17, 2013
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. Biomed Res Int (2014) 0.79
In overweight or obese patients with atrial fibrillation, a weight reduction program reduced symptoms. Ann Intern Med (2014) 0.75
Clopidogrel for smokers and aspirin for nonsmokers?: not so fast. Clin Pharmacol Ther (2014) 0.75
ACP Journal Club. Review: antiplatelet therapies are more effective in smokers than nonsmokers. Ann Intern Med (2014) 0.75
Antiplatelet drugs and the smokers' paradox. Aust Prescr (2015) 0.75
[Clopidogrel cannot yet be exclusively for smokers]. Ned Tijdschr Geneeskd (2014) 0.75
Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis (2017) 0.75
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 16.32
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol (2008) 1.78
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol (2013) 1.65
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos (2003) 1.57
Clopidogrel efficacy and cigarette smoking status. JAMA (2012) 1.52
Drug interactions with smoking. Am J Health Syst Pharm (2007) 1.49
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol (2009) 1.41
The "smoker's paradox" in patients with acute coronary syndrome: a systematic review. BMC Med (2011) 1.13
Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J (2005) 1.09
Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol (2009) 1.07
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J (2012) 0.96
Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet Genomics (2011) 0.95
Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J (2011) 0.91
Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events). J Am Coll Cardiol (2013) 0.90
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA (2008) 6.63
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med (2006) 3.75
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Online social networking by patients with diabetes: a qualitative evaluation of communication with Facebook. J Gen Intern Med (2010) 3.31
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Sending pharma better signals. Science (2005) 2.69
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA (2011) 2.60
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Patients' perceptions of generic medications. Health Aff (Millwood) (2009) 2.54
Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med (2015) 2.53
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation (2008) 2.42
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum (2003) 2.30
Variability in pharmacy interpretations of physician prescriptions. Med Care (2009) 2.18
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum (2007) 2.18
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol (2002) 2.15
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med (2012) 2.13
Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making (2006) 2.12
Trouble getting started: predictors of primary medication nonadherence. Am J Med (2011) 2.09
Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. J Clin Epidemiol (2002) 2.09
Origins of medical innovation: the case of coronary artery stents. Circ Cardiovasc Qual Outcomes (2012) 2.08
Does this patient with a pericardial effusion have cardiac tamponade? JAMA (2007) 2.04
Every clinician deserves an un-sales rep. MedGenMed (2007) 2.03
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.95
Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med (2012) 1.94
Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum (2006) 1.94
Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf (2009) 1.91
Preoperative statin use and postoperative acute kidney injury. Am J Med (2012) 1.87
Unregulated private markets for health care in Canada? Rules of professional misconduct, physician kickbacks and physician self-referral. CMAJ (2004) 1.85
A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol (2005) 1.83
Modes of delivery for interventions to improve cardiovascular medication adherence. Am J Manag Care (2010) 1.83
The variability and quality of medication container labels. Arch Intern Med (2007) 1.83
Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med (2011) 1.82
Value-based insurance design: quality improvement but no cost savings. Health Aff (Millwood) (2013) 1.81
Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol (2007) 1.80
Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int (2003) 1.80
Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol (2008) 1.79
Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med (2004) 1.79
Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol (2008) 1.78
Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med (2014) 1.78
A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol (2003) 1.78
Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension (2005) 1.77
Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum (2006) 1.77
Relationship between COX-2 specific inhibitors and hypertension. Hypertension (2004) 1.75
The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf (2011) 1.74